Equal Costs, Unequal Risk: BBH’s Concentration Versus XPH’s Breadth

A 25‑stock biotech fund that leans heavily on a few large names shows higher volatility and split returns while a 65‑stock pharmaceuticals ETF delivers broader, steadier exposure.

Overview

Both ETFs charge the same 0.35% expense ratio and report a 0.50% trailing 12‑month distribution yield, so headline cost and yield do not explain their different results.
VanEck Biotech ETF (BBH) holds 25 names and is top‑heavy with Amgen at 15%, Gilead Sciences at 12.7%, and Vertex at 9.4%, which raises its sensitivity to those companies’ fortunes.
State Street SPDR S&P Pharmaceuticals ETF (XPH) holds 65 securities and spreads its largest positions across much smaller weights, producing lower historical volatility by the beta measure used in the comparison.
The two funds have diverged materially in trailing total returns over the past year, illustrating that identical fees can mask big differences in performance driven by concentration and company‑specific risk.
Investors should choose based on goals and tolerance: BBH offers higher single‑stock upside and clinical/regulatory risk, XPH offers broader diversification and steadier sector exposure, and launch dates and fund size can affect liquidity and trading costs.